Business Model Breakdown
How electroCore, Inc. Makes Money
ECOR
Market Cap
$79M
Profit Margin
-44.1%
Employees
73
The Short Version
electroCore, Inc. develops and commercializes gammaCore, a non-invasive handheld medical device that delivers vagus nerve stimulation (nVNS) to treat neurological conditions. Its primary focus is on relieving acute pain associated with migraine and cluster headaches. The company generates revenue through the sale of gammaCore devices and recurring sales of associated disposable electrodes or subscription services, targeting patients with a prescription and healthcare providers. The business model leverages proprietary, FDA-approved technology to offer a non-drug alternative for pain management.
Where the Revenue Comes From
gammaCore Device Sales (~60% of revenue)
gammaCore Accessory/Therapy Packs & Subscriptions (~40% of revenue)
Who buys: Patients diagnosed with migraine and cluster headache (via prescription), neurologists, pain specialists, and general practitioners.
Why It Works (Competitive Advantages)
- ✔Proprietary non-invasive vagus nerve stimulation (nVNS) technology with strong patent protection for gammaCore.
- ✔FDA approvals for multiple indications (migraine, cluster headache) providing regulatory validation and market access.
- ✔Established clinical efficacy data supporting product claims.
Economic Moat: Narrow (Intangible Assets/IP (patented nVNS technology), Regulatory Approvals (FDA clearances for specific indications))
What Our Analysis Says
DVR Score as of June 10, 2026
electroCore exhibits strong operational execution, evidenced by Q1 2026 revenue of $9.6M, representing a 42.64% YoY increase, and its gammaCore device addresses a vast market for headache disorders with patented, non-invasive technology. This market potential and product strength are compelling. However, these positives are severely undermined by critical financial distress. The company faces persistent GAAP losses (Q1 2026 net loss of $6.2M), an extremely negative net margin (-64.6% in Q1 2026), and a dangerously low cash position of $10.8M (as of March 31, 2026). Without a substantial and immediate funding event, the high cash burn rate presents an imminent threat of insolvency or significant shareholder dilution, making a clear path to 10x growth highly improbable. The score reflects sustained operational growth tempered by unresolved, paramount financial risk.